Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

CeNeS acquires Cambridge NeuroScience for $2.25/share

Executive Summary

In a stock swap, central nervous system therapeutics developer CeNeS Pharmaceuticals PLC will acquire neuroscience drug discovery firm Cambridge NeuroScience paying in CeNes stock $40.8mm or $2.25 for each Cambridge share, representing a (pr)44% premium. Based on the value of CeNeS stock at the agreement's closing, the transaction price could be as high as $44mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies

UsernamePublicRestriction

Register